<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671736</url>
  </required_header>
  <id_info>
    <org_study_id>Moli1901-010B</org_study_id>
    <secondary_id>EudraCT No 2006-006693-24</secondary_id>
    <nct_id>NCT00671736</nct_id>
  </id_info>
  <brief_title>Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AOP Orphan Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-finding study for the investigational product Lancovutide (Moli1901) in the
      exploratory phase IIb to establish minimum effective dose, optimal dose, and maximum safe
      dose. Additionally, the tolerability of Moli1901 shall be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Moli1901-010B is a multi center, parallel group, placebo controlled, double-blind
      efficacy and safety evaluation of three different dosage schedules of aerosolized Moli1901 in
      adolescents (12 years of age or older), and adults. Study will start with a screening period
      (visit 1) followed by an 8 weeks double blind comparative treatment period (visit 2-7).
      Thereafter, subjects will be observed for additional 4 weeks without treatment (follow-up
      period and visit 8). Spirometry, pulse oximetry and other safety measurements will be
      performed up to 120 min after study medication inhalation. The study will be conducted in 30
      sites in 9 European countries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the percentage of the predicted FEV1 (forced expiratory volume in first second) value</measure>
    <time_frame>at every study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ensemble of two subject reported clinical scores, which are physical dimensions of the self-report, disease-specific quality of life test, the cystic fibrosis questionnaire in the revised version</measure>
    <time_frame>every 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhalation every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhalation twice a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moli1901</intervention_name>
    <description>2,5 ml inhalation solution, 8 weeks treatment period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Lancovutide, 2622U90, duramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moli1901 placebo</intervention_name>
    <description>2,5 ml placebo solution, 8 weeks treatment period</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index

          -  Confirmed diagnosis of cystic fibrosis

          -  FEV1 between 50% and 85% of predicted

          -  Oxygen saturation level measured by pulse oximetry (SpO2) &gt;90 % on room air

        Exclusion Criteria:

          -  Bronchial hyperresponsiveness

          -  Unstable lung function

          -  Pulmonary disease such as pneumonia, tuberculosis, or lung cancer

          -  Acute upper respiratory tract infection within the last 2 weeks

          -  Acute lower respiratory tract infection (requiring antibiotics or hospitalization)
             within the last 4 weeks

          -  Pulmonary exacerbation within the last 4 weeks

          -  Changes from routine maintenance therapy within the last 4 weeks

          -  Scheduled changes to inhaled antibiotics regimen during the course of the study

          -  Receive or are planned to receive any treatment via &quot;on-off&quot; regimen (e.g. Tobramycin
             - TOBI®); last dose of any &quot;on-off&quot; treatment within the last 6 weeks

          -  Any clinically significant liver, renal, cardiac, neurological, or hematological
             disease

          -  ABPA or colonization with Burkholderia cepacia

          -  Poorly controlled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst Eber, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Graz</city>
        <zip>8086</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.aoporphan.com/</url>
    <description>Sponsor</description>
  </link>
  <link>
    <url>http://www.nacfconference.org/</url>
    <description>North American Cystic Fibrosis Conference</description>
  </link>
  <reference>
    <citation>Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Döring G, Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest. 2007 May;131(5):1461-6.</citation>
    <PMID>17494794</PMID>
  </reference>
  <reference>
    <citation>Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest. 2004 Jan;125(1):143-9.</citation>
    <PMID>14718433</PMID>
  </reference>
  <reference>
    <citation>Rickert DE, Dingley K, Ubick E, Dix KJ, Molina L. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem Biol Interact. 2005 Jun 30;155(1-2):55-61.</citation>
    <PMID>15893299</PMID>
  </reference>
  <reference>
    <citation>McNulty MJ, Hutabarat RH, Findlay JW, Devereux K, Knick VC, Harvey RJ, Molina L. Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice. Xenobiotica. 2003 Feb;33(2):197-210.</citation>
    <PMID>12623761</PMID>
  </reference>
  <reference>
    <citation>Zebedin E, Koenig X, Radenkovic M, Pankevych H, Todt H, Freissmuth M, Hilber K. Effects of duramycin on cardiac voltage-gated ion channels. Naunyn Schmiedebergs Arch Pharmacol. 2008 Mar;377(1):87-100. doi: 10.1007/s00210-007-0248-5. Epub 2008 Jan 5.</citation>
    <PMID>18176799</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nina Vartyan-Böhm, PhD</name_title>
    <organization>AOP Orphan Pharmaceuticals AG</organization>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>Moli1901</keyword>
  <keyword>Lancovutide</keyword>
  <keyword>2622U90</keyword>
  <keyword>duramycin</keyword>
  <keyword>lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

